Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial
Muscle & Nerve2016Vol. 55(4), pp. 458–464
Citations Over TimeTop 10% of 2016 papers
Craig Campbell, Hugh J. McMillan, Jean K. Mah, Mark A. Tarnopolsky, Kathryn Selby, Ty McClure, Dawn Wilson, Matthew L. Sherman, Diana M. Escolar, Kenneth M. Attie
Abstract
ACE-031 use demonstrated trends for pharmacodynamic effects on lean mass, fat mass, BMD, and 6MWT. Non-muscle-related adverse events contributed to the decision to discontinue the study. Myostatin inhibition is a promising therapeutic approach for DMD. Muscle Nerve 55: 458-464, 2017.
Related Papers
- → Dominant negative myostatin produces hypertrophy without hyperplasia in muscle(2000)228 cited
- → Interference with Myostatin/ActRIIB Signaling as a Therapeutic Strategy for Duchenne Muscular Dystrophy(2012)62 cited
- → A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle(2002)91 cited
- → Myostatin mRNA expression in patients of Duchenne muscular dystrophy(2011)
- → Progress of myostatin on duchenne muscular dystrophy(2019)